Financial Performance - Q3 2025 revenue reached $17.11 million, a 38% increase from $12.41 million in Q3 2024, marking an all-time high[4] - Gross profit for Q3 2025 was $2.60 million, up 116% from $1.21 million in Q3 2024, the highest quarterly gross profit in company history[4] - Gross margin expanded to a record 15.21%, an improvement of 549 basis points from 9.72% a year earlier[4] - Adjusted EBITDA loss improved 74% to ($0.19 million) in Q3 2025 from ($0.70 million) in Q3 2024[4] Financial Position - Cash position increased to $4.63 million from $0.66 million as of June 30, 2025, reflecting significant improvement in financial flexibility[10] - Total assets rose to $69.49 million, up from $61.84 million as of June 30, 2025, indicating enhanced liquidity and a diversified asset base[10] - Total assets increased to $69.49 billion as of September 30, 2025, up from $61.84 billion in June 2025, representing a growth of 12.7%[20] - Accounts receivable rose to $25.95 billion, a 11.2% increase from $23.36 billion in June 2025[20] - Inventory increased to $5.68 billion, up 11.2% from $5.11 billion in June 2025[20] - Total liabilities reached $46.36 billion, compared to $43.79 billion in June 2025, marking a 5.9% increase[20] - Stockholders' equity decreased to $23.13 billion from $26.18 billion in June 2025, a decline of 11.7%[20] Growth Initiatives - The company secured a $300 million digital financing facility to support growth initiatives and digital asset investments[10] - A contract manufacturing agreement was signed with Medical Pharmaquality for the production of 3 million MYCOFAGYL pessaries annually, expanding the pharmaceutical portfolio[10] - U.S. operations for the Sky Premium Life brand commenced, with all products manufactured locally in GMP-certified facilities[10] - The company expanded Sky Premium Life across the GCC region, entering Oman with an exclusive distribution agreement and an initial purchase order of 42,000 units[10] - The company is expanding its global distribution platform across Europe, Asia, and North America, enhancing its market presence[21] Strategic Partnerships and Acquisitions - Cosmos Health has entered the telehealth sector through the acquisition of ZipDoctor, Inc., broadening its service offerings[21] - The company is focusing on R&D partnerships targeting major health disorders, leveraging AI for drug repurposing technologies[21] - Cosmos Health's product portfolio includes proprietary pharmaceutical and nutraceutical brands, indicating a diversified business model[21] Financing and Risk Management - The company emphasizes the importance of securing financing to implement its business plan amid various risks and uncertainties[22]

Core Insights - Cosmos Health Inc. reported record financial results for Q3 2025, achieving the highest revenue, gross profit, and gross margin in its history, driven by strong performance across all core business segments [2][4][6] Financial Highlights - Q3 2025 revenue reached $17.11 million, a 38% increase from $12.41 million in Q3 2024, marking a new all-time high [4] - For the nine-month period ended September 30, 2025, revenue totaled $45.57 million, up 13% from $40.20 million in the prior-year period [4] - Gross profit for Q3 2025 increased 116% to $2.60 million, compared to $1.21 million in Q3 2024, the highest quarterly gross profit in the company's history [4] - Gross margin expanded to a record 15.21%, up from 9.72% a year earlier, reflecting improved efficiencies and a stronger sales mix [4] - Total operating expenses were $4.42 million in Q3 2025, compared to $3.45 million in Q3 2024, due to strategic investments in talent and new hires [4] Balance Sheet - Total assets increased to $69.49 million, up from $61.84 million as of June 30, 2025, reflecting enhanced liquidity and higher inventory levels [3][9] - Cash and cash equivalents rose sharply to $4.63 million from $0.66 million as of June 30, 2025, indicating significant improvement in financial flexibility [9] - Total liabilities increased to $46.36 million from $35.65 million as of June 30, 2025, due to the strategic utilization of a $300 million financing facility [9] Strategic Initiatives - The company secured a $300 million digital financing facility, enabling the build-up of a substantial digital assets portfolio and supporting long-term growth initiatives [6][9] - Cosmos Health is expanding its proprietary brands globally, including Sky Premium Life and C-Sept/C-Scrub, and has entered the U.S. market with local manufacturing [7][9] - The company signed a contract manufacturing agreement for the production of MYCOFAGYL pessaries, expanding its pharmaceutical portfolio into the gynecology segment [9]

Financial Performance - For the three months ended September 30, 2025, the Company reported revenue of $17,110,425, a 37.8% increase year-over-year, and a net loss of $5,352,890, compared to a net loss of $2,182,534 in the same period of 2024 [326]. - For the nine months ended September 30, 2025, revenue totaled $45,568,655, up 13.4% from $40,202,238 in 2024, while the net loss increased to $8,999,055 from $6,639,935 [326]. - Cost of Goods Sold (COGS) for the three months ended September 30, 2025, was $14,507,807, an increase of 29.5% from $11,204,186 in 2024 [328]. - Gross profit for the three months ended September 30, 2025, was $2,602,618, representing an increase of 115.6% from $1,206,862 in 2024 [330]. - Total operating expenses for the three-month period ended September 30, 2025, were $4,421,333, up 28.3% from $3,446,726 in 2024 [332]. - The Company recognized foreign currency translation gains of $255,263 for Q3 2025, compared to gains of $747,879 in the prior year [338]. - The Company had an accumulated deficit of $123,021,330 and stockholders' equity of $23,134,884 as of September 30, 2025 [347]. - The company reported significant net loss and negative operating cash flows, raising substantial doubt about its ability to continue as a going concern within one year after the issuance of the consolidated financial statements [352]. Capital and Financing - The company expects to continue incurring significant operating losses and may need to reduce costs to sustain operations if additional capital is not secured [293]. - The company has access to additional capital resources through public and private equity offerings, but there is uncertainty regarding obtaining financing on acceptable terms [294]. - The primary source of cash inflows during the nine months ended September 30, 2025, was financing activities, generating net inflows of $9,357,403 [343]. - The company raised capital through the issuance of convertible notes and new third-party debt facilities, including a Securities Purchase Agreement for up to $300 million in senior secured convertible promissory notes, significantly improving liquidity [350]. - The company issued 3,992,541 shares of common stock under its At-the-Market sales program, generating gross proceeds of $4,376,622, enhancing its cash position and liquidity [351]. - The Company anticipates using cash from various sources to conduct its business in the upcoming year, highlighting reliance on external financing [346]. Business Operations and Strategy - The company operates a diversified healthcare group, focusing on proprietary pharmaceutical and nutraceutical brands, with significant growth opportunities through product additions and geographic expansion [300]. - The company launched its proprietary nutraceutical products "Sky Premium Life®" in 2018 and "Mediterranation®" in 2022, with over 160 product codes [306]. - The company signed an exclusive distribution agreement for its Sky Premium Life products in the UAE, anticipating orders of over 3,000,000 units over the next five years [318]. - The company acquired ZipDoctor Inc. for $150,000, enhancing its telemedicine platform capabilities [320]. - The company completed the acquisition of Cana Laboratories for €800,000 and 46,377 shares, enhancing its manufacturing capabilities within the EU [321]. - The acquisition of Bikas is expected to increase annual revenue by more than $10 million and improve gross margins due to economies of scale [324]. - The company plans to expand its portfolio of brand-name and private-label products, launch new distribution channels, and increase sales from exclusive agreements, such as the distribution of Sky Premium Life products in the UAE, which is expected to contribute to operating cash inflows in the near term [349]. - The company aims to enhance its manufacturing capacities and build a multinational network of wholesalers, distributors, and pharmacies while expanding its portfolio of innovative products [356]. - The company is focusing on high-margin segments and has shown strong performance in proprietary brands such as Sky Premium Life, Mediterranation, and C-Sept/C-Scrub, with launches into new geographical regions [360]. - The company is optimizing its production facilities and establishing a global footprint in the pharmaceutical fields of contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) [360]. - The company intends to invest in R&D to deliver innovative products, including treatments for obesity, gastrointestinal disorders, and various cancers, as well as an AI-driven drug repurposing platform [360]. - The company’s product portfolio includes generics, OTC pharmaceutical products, innovative medicines, and nutraceuticals, optimizing product lifecycle across therapeutic areas [362]. - The company is committed to driving organic growth at attractive margins by improving execution, optimizing cash flow, and leveraging its strong market position [357]. Accounting and Financial Reporting - The Company has net operating loss carry-forwards applicable to future taxable income in the United States, but potential benefits have not been recognized due to uncertainty in utilization [384]. - The Company follows ASC 310 to estimate the allowance for doubtful accounts, reviewing each trade receivable for collectability and adjusting credit limits based on payment history [385]. - Merchandise inventories are valued at the lower of cost or market using the weighted-average cost method, with reserves for damaged and slow-moving items recorded annually [386]. - The Company accounts for its convertible promissory note at fair value, with changes recorded as non-operating loss in the consolidated statements of operations [388]. - The fair value of the convertible promissory note is estimated using a Monte Carlo simulation model, considering factors such as stock volatility and risk-free interest rates [389]. - Digital assets are recorded at cost and measured at fair value, with changes recognized in the consolidated statement of income as "Gain (loss) on digital assets" [390][391]. - As of September 30, 2025, the Company had 31,869,041 common shares issued and outstanding, with an additional 26,305,652 common shares issuable upon conversion of convertible notes and exercise of warrants [392].

Core Insights - Cosmos Health Inc. has initiated a new research and development program utilizing nanotechnology to enhance the effectiveness of phytochemical constituents in dietary supplements [1][2] - The new initiative builds on the proprietary technology developed during the creation of CCX Hydrogel, focusing on plant-based extract-loaded phytosomes to improve absorption, stability, and bioactivity of phytochemicals [2][5] - The company emphasizes a sustainable, solvent-free process for creating phytosomes, aligning with its commitment to environmentally responsible practices [3][5] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [6] - The company manufactures a range of products, including pharmaceuticals, food supplements, cosmetics, and medical devices, under European Good Manufacturing Practices (GMP) [6] - Cosmos Health has established R&D partnerships targeting major health disorders and has entered the telehealth space through the acquisition of ZipDoctor, Inc. [6]

Core Insights - Cosmos Health Inc. has acquired an additional $200,000 worth of Ethereum, increasing its total investment in ETH to $2 million [1][2][3] - The acquisition is part of a broader strategy supported by a $300 million digital assets facility aimed at diversifying and strengthening the company's portfolio through targeted digital asset investments [2][3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada [3] - The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands and operates manufacturing under European Good Manufacturing Practices (GMP) [3] - It distributes a wide range of pharmaceuticals and parapharmaceuticals through subsidiaries in Greece and the UK, and has established R&D partnerships targeting major health disorders [3] Strategic Focus - The CEO of Cosmos Health emphasized the importance of reaching the $2 million milestone in Ethereum investment as a significant step in the company's digital asset expansion strategy [3] - The company is committed to leveraging its $300 million financing facility to further diversify and enhance its long-term asset base [3]

Core Insights - Cosmos Health Inc. has acquired an additional $200,000 worth of Ethereum, increasing its total investment in ETH to $2 million [1][2][3] - The acquisition is part of a broader strategy supported by a $300 million digital assets facility aimed at diversifying and strengthening the company's portfolio through targeted digital asset investments [2][3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada [3] - The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands and operates manufacturing under European Good Manufacturing Practices (GMP) [3] - It distributes a wide range of pharmaceuticals and parapharmaceuticals through subsidiaries in Greece and the UK, and has established R&D partnerships targeting major health disorders [3] - The company has entered the telehealth space through the acquisition of ZipDoctor, Inc. and is expanding its operations globally [3]

Core Points - Cosmos Health Inc. has regained compliance with Nasdaq Listing Rule 5550(a)(2), confirming a minimum bid price of $1.00 per share [1][2] - The compliance was achieved organically over 18 consecutive business days, with the closing bid price at or above $1.00 from September 22, 2025, to October 15, 2025 [2] - CEO Greg Siokas emphasized the importance of this achievement as a reflection of the company's strategic initiatives and strengthening fundamentals [3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada [4] - The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands and operates under European Good Manufacturing Practices (GMP) [4] - Cosmos Health manufactures and distributes a wide range of pharmaceuticals and parapharmaceuticals, with a focus on R&D partnerships targeting major health disorders [4] - The company has entered the telehealth space through the acquisition of ZipDoctor, Inc. and is expanding its global distribution platform [4]

Core Insights - Cosmos Health Inc. has increased its investment in Ethereum (ETH) to a total of $1.8 million by purchasing an additional $300,000 worth of ETH [1][3] - The purchase is part of a broader strategy under a $300 million digital assets facility aimed at diversifying the company's portfolio through strategic digital asset investments [2][3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada [3] - The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands and operates manufacturing under European Good Manufacturing Practices (GMP) [3] - It distributes pharmaceuticals and parapharmaceuticals through subsidiaries in Greece and the UK and has established R&D partnerships targeting major health disorders [3]

Core Insights - Cosmos Health Inc. has increased its investment in Ethereum (ETH) by an additional $500,000, raising its total investment to $1.5 million [1][2][3] - The acquisition is part of a larger $300 million digital assets facility aimed at diversifying the company's balance sheet and leveraging blockchain technology in healthcare [2][3] - The CEO of Cosmos Health expressed optimism about the potential for further appreciation of Ethereum, viewing it as both a long-term investment and a means to enable secure, decentralized healthcare solutions [3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada [4] - The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands and operates manufacturing facilities compliant with European Good Manufacturing Practices [4] - Cosmos Health distributes a wide range of pharmaceuticals and parapharmaceuticals and has established R&D partnerships targeting major health disorders, enhanced by AI drug repurposing technologies [4] - The company has entered the telehealth space through the acquisition of ZipDoctor, Inc. and is expanding its operations across Europe, Asia, and North America [4]

Core Insights - Cosmos Health Inc. has entered into an exclusive distribution agreement with Diyar United for its Sky Premium Life® nutraceuticals in Kuwait, marking a strategic expansion into the Middle Eastern market [1][2][6] - The agreement grants Diyar United exclusive rights for the registration, promotion, logistics, and distribution of various food supplements, including collagen, vitamins, and herbal blends [3][4] - The initial purchase order exceeds 65,000 units, indicating strong demand and a growing sales pipeline in Kuwait [4] Market Opportunity - Kuwait's nutritional supplements market was valued at approximately $1.16 billion in 2024 and is projected to reach $1.68 billion by 2030, growing at a CAGR of around 6.3%, presenting a significant opportunity for Cosmos Health [5] - The partnership with Diyar United, a respected distributor with extensive healthcare experience, is expected to enhance Cosmos Health's market penetration in Kuwait [2][6] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group with a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life® [7] - The company operates under European Good Manufacturing Practices (GMP) and is involved in the manufacturing and distribution of pharmaceuticals, food supplements, and medical devices across Europe, Asia, and North America [7] - Cosmos Health is also engaged in R&D partnerships targeting major health disorders and has entered the telehealth space through the acquisition of ZipDoctor, Inc. [7]